Biocon has acquired a 60,000 square feet research and development site from Pfizer to “fast-forward” its biosimilars development. Subsidiary Biocon Biologics, set up in 2017 by Biocon as a separate subsidiary to house its biologics assets, described the “bench-to-pilot-scale” biologics research facility, located in the southern Indian city of Chennai, as “state-of-the-art.” The facility will house over 250 scientists who will have access to R&D labs equipped with over 500 high-end process and analytical instruments.
“This investment will allow us to fast-forward development of our biosimilars from lab to pilot scale,” said Biocon Biologics chief...





